Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lonza GroupFRA:LO3 -0.73%83 EV-to-EBITDA is 28.11 as of Aug. 06, 2026, which is 17% above its 10-year median of 24.10. GuruFocus rates FRA:LO3 with a GF Score™ of 83/100 and a GF Value™ of €617.61 (Fairly Valued). The stock has 4 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Lonza Group ranks worse than 72.27% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lonza Group's enterprise value is €45,997 Mil.
Lonza Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €1,636 Mil. Therefore, Lonza Group's EV-to-EBITDA for today is 28.11.
The historical rank and industry rank for Lonza Group's EV-to-EBITDA or its related term are showing as below:
FRA:LO3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.31 Med: 24.1 Max: 43.93
Current: 28.02
During the past 13 years, the highest EV-to-EBITDA of Lonza Group was 43.93. The lowest was 11.31. And the median was 24.10.
FRA:LO3's EV-to-EBITDA is ranked worse than 72.27% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.18
vs FRA:LO3: 28.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lonza Group's PE Ratio (TTM) for today is calculated as:
Lonza Group's share price for today is €600.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.551.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Lonza Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LO3 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Lonza Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lonza Group's EV-to-EBITDA falls into.
Lonza Group's current Enterprise Value is €45,997 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €1,636 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (FRA:LO3) has a EV-to-EBITDA of 28.11 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lonza Group. This is 17% above median its historical median of 24.10. Over the past decade, Lonza Group's EV-to-EBITDA has ranged from 11.31 to 43.93. According to the industry distribution chart, Lonza Group ranks #86 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 72.3%.
Is Lonza Group's EV-to-EBITDA too high?
Lonza Group's current EV-to-EBITDA of 28.11 is 17% above median its 10-year median of 24.10. Over the past 10 years, this metric has ranged from a low of 11.31 to a high of 43.93. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.18. Lonza Group's value of 28.11 is 85.2% above this industry median. Based on the distribution chart, Lonza Group ranks #86 out of 119 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lonza Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #86 out of 119 companies for EV-to-EBITDA. This places Lonza Group in the lower half of its industry. The industry median EV-to-EBITDA is 15.18. Lonza Group's value of 28.11 is 85.2% above this benchmark. Historically, Lonza Group's own EV-to-EBITDA has ranged from 11.31 to 43.93 over the past decade. While the company's 10-year median is 24.10 vs. the industry median of 15.18, Lonza Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.18, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current EV-to-EBITDA of 28.11 is 85.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lonza Group. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current EV-to-EBITDA is 28.11, which is 17% above median its own 10-year median of 24.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (FRA:LO3) is currently considered Fairly Valued. The stock's GF Value™ is €617.61, compared to a current price of €600.40 — trading 2.8% below its estimated fair value. The current EV-to-EBITDA is 28.11, which is 17% above median its 10-year median of 24.10 and 85.2% above the Medical Diagnostics & Research industry median of 15.18. Lonza Group's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lonza Group (FRA:LO3), the current EV-to-EBITDA is 28.11 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (FRA:LO3) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of €600.40 is trading 2.8% below its estimated GF Value™ of €617.61.
GuruFocus considers Lonza Group to be Fairly Valued.
Key valuation signals for FRA:LO3:
EV-to-EBITDA: 28.11 (17% above median its 10-year median of 24.10)
GF Value™: €617.61 vs. price of €600.40 (2.8% below fair value)
Industry Position: 85.2% above the Medical Diagnostics & Research median (#86 of 119)
No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
83GF Score
Get the complete analysis for FRA:LO3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LO3 has been successfully added to your 
